For the quarter ended December 2025, Idex (IEX) reported revenue of $899.1 million, up 4.2% over the same period last year. EPS came in at $2.10, compared to $2.04 in the year-ago quarter.
The reported revenue represents a surprise of +1.99% over the Zacks Consensus Estimate of $881.58 million. With the consensus EPS estimate being $2.04, the EPS surprise was +3.11%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Idex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net sales - Organic impact - YoY change: 1% compared to the -1% average estimate based on two analysts.
- Net Sales- Fluid & Metering Technologies (FMT): $305.5 million versus $310.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.1% change.
- Intersegment sales eliminations: $-1.7 million compared to the $-2.39 million average estimate based on three analysts. The reported number represents a change of -32% year over year.
- Net Sales- Fire & Safety/Diversified Products (FSDP): $187.6 million versus $182.77 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -2.8% change.
- Net Sales- Health & Science Technologies (HST): $407.7 million versus $390.18 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
- Adjusted EBITDA- Fluid & Metering Technologies (FMT): $96 million versus the three-analyst average estimate of $106.14 million.
- Adjusted EBITDA- Corporate: $-18.7 million versus $-25.33 million estimated by three analysts on average.
- Adjusted EBITDA- Fire & Safety/Diversified Products (FSDP): $53.6 million compared to the $51.24 million average estimate based on three analysts.
- Adjusted EBITDA- Health & Science Technologies (HST): $110 million versus $104.62 million estimated by three analysts on average.
View all Key Company Metrics for Idex here>>>
Shares of Idex have returned +9.7% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
IDEX Corporation (IEX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
